New Zealand markets open in 5 hours 31 minutes

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
20.40-0.78 (-3.68%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 307.75M
Enterprise value 223.64M
Trailing P/E 0.53
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.92
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.30

Trading information

Stock price history

Beta (5Y monthly) 2.22
52-week change 355.73%
S&P500 52-week change 322.36%
52-week high 331.01
52-week low 34.00
50-day moving average 324.77
200-day moving average 313.44

Share statistics

Avg vol (3-month) 3114.95k
Avg vol (10-day) 378.45k
Shares outstanding 515.09M
Implied shares outstanding 615.09M
Float 89.47M
% held by insiders 15.01%
% held by institutions 160.94%
Shares short (15 Apr 2024) 4492.42k
Short ratio (15 Apr 2024) 44.96
Short % of float (15 Apr 2024) 43.31%
Short % of shares outstanding (15 Apr 2024) 43.26%
Shares short (prior month 15 Mar 2024) 4327.3k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 304 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-60.09%
Return on equity (ttm)-112.67%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -67.75M
Net income avi to common (ttm)-64.47M
Diluted EPS (ttm)-61.80
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)86.89M
Total cash per share (mrq)5.77
Total debt (mrq)2.79M
Total debt/equity (mrq)3.55%
Current ratio (mrq)7.19
Book value per share (mrq)7.03

Cash flow statement

Operating cash flow (ttm)-52.07M
Levered free cash flow (ttm)-30.35M